Publications by authors named "Shinichi Hasako"

Claim this Profile
T
TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant Mutations.
Hibiki Udagawa, Shinichi Hasako, Akihiro Ohashi, Rumi Fujioka, Yumi Hakozaki

Mol Cancer Res· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations.
Shinichi Hasako, Miki Terasaka, Naomi Abe, Takao Uno, Hirokazu Ohsawa

Mol Cancer Ther· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Muscle RAS oncogene homolog (MRAS) recurrent mutation in Borrmann type IV gastric cancer.
Makiko Yasumoto, Etsuko Sakamoto, Sachiko Ogasawara, Taro Isobe, Junya Kizaki, Shinichi Hasako

Cancer Med· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo.
Hiroshi Hirai, Ikuko Takahashi-Suziki, Toshiyasu Shimomura, Kazuhiro Fukasawa, Takumitsu Machida, Shinichi Hasako

Invest New Drugs· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo.
Hiroshi Hirai, Toshiyasu Shimomura, Makiko Kobayashi, Tomohiro Eguchi, Eri Taniguchi, Shinichi Hasako

Cell Cycle· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
Toshiyasu Shimomura, Shinichi Hasako, Yoko Nakatsuru, Takashi Mita, Koji Ichikawa

Mol Cancer Ther· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis